We are an emerging leader in the global cannabis industry.

Emerald Health Therapeutics is a Health Canada Licensed Producer of medical cannabis. A vertically integrated, seed-to-sale enterprise, Emerald has combined core competencies from decades of experience in pharmaceutical innovation with large-scale agriculture expertise. Our ambition is to be at the forefront of developing knowledge and products that provide wellness and health benefits from cannabis.

 

Emerald believes the next wave of adult users and medical consumers of cannabis products will demand consistent dosing and alternative methods of consumption with safety assured through GMP compliant production.

— Executive Chairman, Avtar Dhillon, MD

GROWTH

Emerald’s multi-phase expansion plan is timed for massive scaling to meet anticipated demand from a legalized recreational cannabis market. Our multi-phase plan on our 32-acre site in Metro Vancouver includes modular expansion to 500,000 sf of growing capacity by the end of 2018, with total potential of 1 million sf. In our 50%-owned Pure Sunfarms partnership, we plan to have 500,000 sf of our 1.1 million sf existing greenhouse converted into cannabis production by the end of 2018. We expect to significantly increase cannabis sales in conjunction with the onset of adult use legalization slated for July 2018.

PRODUCTS

With an industry-leading pool of cannabis genetics and a strong focus on product innovation backed by decades of rigorous pharmaceutical industry R&D and clinical development, Emerald is putting in place the components for creating consistent high-value downstream products for both the recreational and medical markets. We believe cannabinoid medicines present an unparalleled opportunity for use as therapeutic alternatives to a host of conventional pharmaceutical medicines that are typically much more toxic, potentially less efficacious, and often highly addictive. Emerald expects that proprietary intellectual property created through its product innovation efforts will be beneficial in creating competitive advantages as well as consumer confidence and product preference for a growing new wave of adult users.

To learn more about Emerald’s products, please visit https://www.emerald.care/

Our ultimate goal is to develop standardized pharmaceutical dosage medication in a pill or capsule format. We plan to initiate several clinical studies to that end in 2017.

— President & CEO, Bin Huang, PhD, MBA

PEOPLE

Emerald’s leadership is among the industry’s most experienced in pharmaceutical drug discovery, development, production, and distribution. Team members have extensive hands-on experience in clinical research, GMP production practices, regulatory approval processes, and intellectual property creation.

Meet the Team

Get in touch with us…

The total market size potential of recreational marijuana in Canada is more than $22.6 billion.

— Source: Deloitte, Recreational Marijuana: Insights and Opportunities